Chromosomal analysis of<unk>  shows the breaking and joining of two chromosomes in the tumor cells. A piece of chromosome X breaks and is joined to chromosome 17. This translocation creates a fusion between two genes named ASPL and TFE3, which results in the formation of an aberrant protein (termed fusion protein) that is not found in normal cells. Two sorts of fusions between chromosome X and chromosome 17 are found in different<unk>  tumors: type one and type two. Dr. Marc Ladanyi at Memorial Sloan-Kettering Cancer Center, in New York City, has pioneered this work. The resultant fusion protein ASPL–TFE3 is a rogue transcription factor that is the driver of aberrant cellular behavior including uncontrolled cell division and enhanced angiogenesis.
Alveolar soft part sarcoma
Angiomatoid fibrous histiocytoma
Epithelioid sarcoma
Mast cell sarcoma
Hemangiosarcoma
Oncocytoma
Mycetoma
Hemangioendothelioma